



## Advances in Anticancer Drugs and Pharmacotherapy of Cancer

Guest Editors:

**Dr. Muhammad Abdul Hadi**

Department of Clinical Pharmacy  
and Practice, College of  
Pharmacy, QU Health, Qatar  
University, Doha P.O. Box 2713,  
Qatar

**Dr. Md. Sanower Hossain**

Centre for Sustainability of  
Ecosystem and Earth Resources  
(Pusat ALAM), Universiti Malaysia  
Pahang, Kuantan 26300, Pahang,  
Malaysia

**Dr. Bey-Hing Goh**

Sunway Biofunctional Molecules  
Discovery Centre, School of  
Medical and Life Sciences,  
Sunway University, Petaling Jaya  
47500, Selangor Darul Ehsan,  
Malaysia

### Message from the Guest Editors

The pharmacotherapy of cancer has experienced some encouraging novel developments. A new armamentarium of anticancer drugs and their delivery have led to improvements not only in efficacy and safety profiles but also the quality of life both pre and post treatment.

This Special Issue of *Cancers* will cover theoretical and applied aspects of cancer drug discovery, formulation, product development, and clinical practices. Submissions presenting research related to chemical identification, in vitro/in vivo/in silico evaluation of anticancer agents, including natural products, or complementary medicine in original research and review articles are welcome.

Deadline for manuscript  
submissions:

**closed (15 October 2023)**





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)